Therapeutic Potential of Oral Factor Xa Inhibitors
- 23 December 2010
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 363 (26), 2559-2561
- https://doi.org/10.1056/nejme1012149
Abstract
Venous thromboembolism is the third leading cause of cardiovascular death, after myocardial infarction and stroke.1 Total hip or knee arthroplasty is the procedure with the highest risk of venous thromboembolism.2 In this issue of the Journal, two studies affirm and extend the efficacy and safety of the novel oral factor Xa inhibitors, rivaroxaban and apixaban, in the management of venous thromboembolic disease.3,4 In the Acute DVT Study,3 rivaroxaban (at a dose of 15 mg twice daily for 3 weeks, followed by 20 mg once daily) was compared with enoxaparin followed by warfarin or acenocoumarol, for 3, 6, or 12 . . .Keywords
This publication has 6 references indexed in Scilit:
- Apixaban versus Enoxaparin for Thromboprophylaxis after Hip ReplacementNew England Journal of Medicine, 2010
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.Clinical Pharmacokinetics, 2009
- The Epidemiology of Venous ThromboembolismCirculation, 2003
- Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous ThromboembolismNew England Journal of Medicine, 2003
- Physician practices in the management of venous thromboembolism: A community-wide surveyJournal of Vascular Surgery, 1992